A validated model of serum anti-müllerian hormone from conception to menopause.
Anti-Müllerian hormone (AMH) is a product of growing ovarian follicles. The concentration of AMH in blood may also reflect the non-growing follicle (NGF) population, i.e. the ovarian reserve, and be of value in predicting reproductive lifespan. A full description of AMH production up to the menopaus...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3137624?pdf=render |
_version_ | 1818572837112250368 |
---|---|
author | Thomas W Kelsey Phoebe Wright Scott M Nelson Richard A Anderson W Hamish B Wallace |
author_facet | Thomas W Kelsey Phoebe Wright Scott M Nelson Richard A Anderson W Hamish B Wallace |
author_sort | Thomas W Kelsey |
collection | DOAJ |
description | Anti-Müllerian hormone (AMH) is a product of growing ovarian follicles. The concentration of AMH in blood may also reflect the non-growing follicle (NGF) population, i.e. the ovarian reserve, and be of value in predicting reproductive lifespan. A full description of AMH production up to the menopause has not been previously reported.By searching the published literature for AMH concentrations in healthy pre-menopausal females, and using our own data (combined n = 3,260) we have generated and robustly validated the first model of AMH concentration from conception to menopause. This model shows that 34% of the variation in AMH is due to age alone. We have shown that AMH peaks at age 24.5 years, followed by a decline to the menopause. We have also shown that there is a neonatal peak and a potential pre-pubertal peak. Our model allows us to generate normative data at all ages.These data highlight key inflection points in ovarian follicle dynamics. This first validated model of circulating AMH in healthy females describes a transition period in early adulthood, after which AMH reflects the progressive loss of the NGF pool. The existence of a neonatal increase in gonadal activity is confirmed for females. An improved understanding of the relationship between circulating AMH and age will lead to more accurate assessment of ovarian reserve for the individual woman. |
first_indexed | 2024-12-15T00:02:58Z |
format | Article |
id | doaj.art-f79f12cf69f1477087384f420ac58fae |
institution | Directory Open Access Journal |
issn | 1932-6203 |
language | English |
last_indexed | 2024-12-15T00:02:58Z |
publishDate | 2011-01-01 |
publisher | Public Library of Science (PLoS) |
record_format | Article |
series | PLoS ONE |
spelling | doaj.art-f79f12cf69f1477087384f420ac58fae2022-12-21T22:42:51ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-0167e2202410.1371/journal.pone.0022024A validated model of serum anti-müllerian hormone from conception to menopause.Thomas W KelseyPhoebe WrightScott M NelsonRichard A AndersonW Hamish B WallaceAnti-Müllerian hormone (AMH) is a product of growing ovarian follicles. The concentration of AMH in blood may also reflect the non-growing follicle (NGF) population, i.e. the ovarian reserve, and be of value in predicting reproductive lifespan. A full description of AMH production up to the menopause has not been previously reported.By searching the published literature for AMH concentrations in healthy pre-menopausal females, and using our own data (combined n = 3,260) we have generated and robustly validated the first model of AMH concentration from conception to menopause. This model shows that 34% of the variation in AMH is due to age alone. We have shown that AMH peaks at age 24.5 years, followed by a decline to the menopause. We have also shown that there is a neonatal peak and a potential pre-pubertal peak. Our model allows us to generate normative data at all ages.These data highlight key inflection points in ovarian follicle dynamics. This first validated model of circulating AMH in healthy females describes a transition period in early adulthood, after which AMH reflects the progressive loss of the NGF pool. The existence of a neonatal increase in gonadal activity is confirmed for females. An improved understanding of the relationship between circulating AMH and age will lead to more accurate assessment of ovarian reserve for the individual woman.http://europepmc.org/articles/PMC3137624?pdf=render |
spellingShingle | Thomas W Kelsey Phoebe Wright Scott M Nelson Richard A Anderson W Hamish B Wallace A validated model of serum anti-müllerian hormone from conception to menopause. PLoS ONE |
title | A validated model of serum anti-müllerian hormone from conception to menopause. |
title_full | A validated model of serum anti-müllerian hormone from conception to menopause. |
title_fullStr | A validated model of serum anti-müllerian hormone from conception to menopause. |
title_full_unstemmed | A validated model of serum anti-müllerian hormone from conception to menopause. |
title_short | A validated model of serum anti-müllerian hormone from conception to menopause. |
title_sort | validated model of serum anti mullerian hormone from conception to menopause |
url | http://europepmc.org/articles/PMC3137624?pdf=render |
work_keys_str_mv | AT thomaswkelsey avalidatedmodelofserumantimullerianhormonefromconceptiontomenopause AT phoebewright avalidatedmodelofserumantimullerianhormonefromconceptiontomenopause AT scottmnelson avalidatedmodelofserumantimullerianhormonefromconceptiontomenopause AT richardaanderson avalidatedmodelofserumantimullerianhormonefromconceptiontomenopause AT whamishbwallace avalidatedmodelofserumantimullerianhormonefromconceptiontomenopause AT thomaswkelsey validatedmodelofserumantimullerianhormonefromconceptiontomenopause AT phoebewright validatedmodelofserumantimullerianhormonefromconceptiontomenopause AT scottmnelson validatedmodelofserumantimullerianhormonefromconceptiontomenopause AT richardaanderson validatedmodelofserumantimullerianhormonefromconceptiontomenopause AT whamishbwallace validatedmodelofserumantimullerianhormonefromconceptiontomenopause |